<DOC>
	<DOCNO>NCT00874250</DOCNO>
	<brief_summary>To assess safety efficacy GORE Conformable TAG® Thoracic Endoprosthesis primary treatment aneurysm descend thoracic aorta ( DTA ) &gt; Primary Hypothesis : The proportion subject free major device event 1 month post-treatment significantly less 0.95 , represent proportion observe previous clinical study GORE TAG® Thoracic Endoprosthesis</brief_summary>
	<brief_title>Thoracic Endoprosthesis Treatment Aneurysm Descending Thoracic Aortic</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<criteria>1 . Presence DTA aneurysm deem warrant surgical repair &gt; Fusiform ( ≥50 mm ) , &gt; Saccular ( diameter criterion ) 2 . Subject &gt; 21 year age &gt; 3 . Proximal distal land zone length ≥ 2.0 cm Landing zone must native aorta Landing zone may include left subclavian artery , necessary 4 . All proximal distal land zone inner diameter 1642 mm &gt; • Diameter assess flow lumen thrombus , present ; calcium exclude &gt; 5 . Life expectancy &gt; 2 year &gt; 6 . Able tolerate thoracotomy &gt; 7 . Male infertile female &gt; 8 . Able comply protocol requirement include followingup &gt; 9 . Signed informed consent &gt; &gt; &gt; 1 . Differing proximal distal neck diameter ( aortic taper ) outside intend aortic diameter requirement ( size guide ) single endoprosthesis diameter inability use device different diameter ( adherence size guide ) compensate taper &gt; 2 . Tortuous stenotic iliac and/or femoral artery inability use conduit vascular access &gt; 3 . Aneurysmal , dissect , heavily calcify , heavily thrombose land zone ( ) &gt; 4 . Mycotic aneurysm &gt; 5 . Hemodynamically unstable aneurysm rupture &gt; 6 . Aortic dissection &gt; 7 . Planned coverage leave carotid celiac artery CTAG Device &gt; 8 . Planned concomitant surgical procedure ( left subclavian transposition wireless sac pressure monitoring ) , major surgery within 30 day treatment date &gt; 9 . Known degenerative connective tissue disease , e.g . Marfan EhlerDanlos Syndrome &gt; 10 . Known history drug abuse &gt; 11 . ASA risk classification = V ( moribund patient expect live 24 hour without operation ) &gt; 12 . NYHA class IV &gt; 13 . Participating another investigational device drug study within 1 year treatment &gt; 14 . Subject known sensitivity allergies device material &gt; 15 . Subject systemic infection may increase risk endovascular graft infection &gt;</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>